Icono twitter
Linkedin
Congress

Cost-effectiveness of ruxolitinib vs. Best Available Therapy in the treatment of myelofibrosis in Spain

Authors: Gómez-Casares MT, Hernández-Boluda JC, Jiménez-Velasco A, Martínez-López J, Ferrario MG, Gozalbo Irmina, Gostkorzewicz J, Subirá R

Year: 2017

Congress: XXXVII Jornadas de la Economía de la Salud (AES)


Download PDF
Subscribe to Outcomes´10
Todos los campos marcados con un * son obligatorios
Responsible for the data: Outcomes'10, s.l.u., Purpose: Sending commercial communications. Legitimation: Art. 6.1 Consent of the interested party. Recipient: No data is transferred unless expressly authorised. You may exercise your rights on data protection (access, rectification, opposition, deletion, automated decisions, limitation of treatment, portability) by email at dpo@outcomes10.com. Data will be retained for the time necessary to fulfill its purpose and derived responsibilities by current regulations and the deadlines in the applicable regulations on archives and documentation. In any case, you can request the protection of the Spanish Data Protection Agency through its website www.aepd.es/. In addition, you can consult more information on the privacy policy
logo outcomes
Aenor gestión de calidad
Aenor seguridad e información
Logotipo
Skip to content
Powered by  GDPR Cookie Compliance
Privacy Summary

This website uses cookies so that we can offer you the best possible user experience. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website or helping our team understand which sections of the website you find most interesting and useful.